MindMed

Generalized Anxiety Disorder and ADHD were the most common diagnoses in 2023, as mental health diagnoses in the US surged nearly 40% between 2019 and 2023. This increase reflects a positive shift towards seeking help and destigmatizing mental health conditions, driven by changing societal attitudes and improved access to care. Read more: https://lnkd.in/gY6UpqaW

Generalized Anxiety Disorder (GAD) is one of the most prevalent anxiety disorders but remains under-diagnosed and often under-treated. This oversight may lead to significant economic impact. MindMed's latest research explores the healthcare resource use associated with Generalized Anxiety Disorder (GAD) among U.S. adults. This comprehensive study examines various aspects, including the frequency of medical visits, the types of medications prescribed, hospital admissions, and the use of emergency services. Understanding these trends is crucial for optimizing treatment strategies, improving patient outcomes, and ensuring efficient resource allocation. Our commitment at MindMed is to enhance mental health care through innovative research and targeted interventions.

MindMed reported Second Quarter 2024 financial results and business updates. For full details, read the Press Release here: https://lnkd.in/d_RCfUp6

Research shows promising advancements in psychedelic medicine. Reid Robison, Senior Principal Investigator at Numinus shares insights on how MindMed’s investigational treatment in development may significantly advance mental health treatment. Watch the video here: https://lnkd.in/dppFyEqH #PsychedelicMedicine #MentalHealth #Mindmed

MindMed is in the running for a panel at SXSW 2025, and we need your support! Anxiety is a growing burden and many patients are underserved. Our panel, "Understanding Anxiety Inside Out – Beyond the Emotions," will take inspiration from the beloved movie Inside Out 2 to explore the complexities of anxiety from a whole new perspective. We will explore the broader implications of anxiety disorders, as well as the latest developments in anxiety treatments, uncovering innovative solutions and addressing ongoing unmet medical needs in mental health. 🗳️ Every vote counts, so please take a moment to cast yours before the deadline on Sunday, August 18th. Vote here: https://lnkd.in/gYZuXyHm

We're excited to announce that MindMed will be participating in the upcoming Canaccord Genuity Group Inc. Conference! This prestigious annual event brings together institutional investors from around the world. We're delighted to share with them our insights about the significant unmet needs in treating Generalized Anxiety Disorder and our vision for the potential of MM120, our lead product which will be entering Phase III clinical trials later this year. We look forward to connecting with industry leaders and investors to discuss our latest advancements and our commitment to shaping the future of mental health.

Join us on August 13, 2024, at 8:00 AM ET for our quarterly earnings conference call where we will discuss our Q2 2024 financial results and provide business updates. Register here: https://lnkd.in/eDqZXCPR Read the full press release here: https://lnkd.in/eXZEpDxn

"Our mission at MindMed is to push the boundaries of mental health treatment. We believe in the potential of psychedelics to transform lives and bring hope to those with GAD." - Robert Barrow, CEO of MindMed At MindMed, we're dedicated to revolutionizing mental health care through cutting-edge research and development. Our team is focused on creating innovative, science-backed treatments to improve the lives of those with Generalized Anxiety Disorder (GAD). By harnessing the therapeutic potential of psychedelics, we aim to address not just symptoms, but the root causes of mental health conditions. Our holistic approach strives to offer patients a better quality of life, free from the constraints of traditional medications.

“MindMed is pioneering the future of brain health with potential groundbreaking treatments, and I am thrilled to join a company dedicated to transforming patient outcomes in an area of immense public health need,” - Stephanie Fagan, newly appointed Chief Corporate Affairs Officer of MindMed We’re excited to welcome Stephanie Fagan to the MindMed team, as Chief Corporate Affairs Officer. With over 20 years of experience as an executive in the healthcare industry, Ms. Fagan will serve as an executive team member, overseeing public affairs and corporate communications.

1̳9̳5̳0̳-̳1̳9̳6̳0̳ Psychedelic research blossomed to reveal innovative approaches to treatments, showing the potential of psychedelics to enhance emotional insight and facilitate profound psychological breakthroughs. As we build upon this rich history, we're working to shape a brighter future for mental health care, with innovative treatments that offer hope to individuals suffering from mental health issues. #psychedelics #MentalHealth